Cargando…
215. Shorter vs. Longer Duration of Treatment in Patients with Ceftriaxone-resistant and Ceftriaxone-susceptible Escherichia coli Bloodstream Infections
BACKGROUND: Several randomized controlled trials (RCT) have shown that short-course (∼7 days) antibiotic treatment is non-inferior to longer antibiotic courses (∼14 days) in patients with uncomplicated bloodstream infection (BSI) with mostly susceptible Gram-negative bacteria. Here, we evaluate shor...
Autores principales: | Mackow, Natalie A, Ge, Lizhao, Komarow, Lauren, Shao, Wanying, Herc, Erica, Doi, Yohei, Arias, Cesar A, Albin, Owen, Saade, Elie, Miller, Loren G, Jacob, Jesse T, Satlin, Michael J, Krsak, Martin, Huskins, W Charles, Dhar, Sorabh, Shelburne, Samuel A, Hill, Carol, Greenwood-Quaintance, Kerryl E, Schmidt-Malan, Suzannah, Patel, Robin, Fowler, Vance G, Tamma, Pranita, van Duin, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678723/ http://dx.doi.org/10.1093/ofid/ofad500.288 |
Ejemplares similares
-
Clinical Impact of Ceftriaxone Resistance in Escherichia coli Bloodstream Infections: A Multicenter Prospective Cohort Study
por: Tamma, Pranita D, et al.
Publicado: (2022) -
Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?
por: Tamma, Pranita D, et al.
Publicado: (2018) -
PRO: Testing for ESBL production is necessary for ceftriaxone-non-susceptible Enterobacterales: perfect should not be the enemy of progress
por: Tamma, Pranita D, et al.
Publicado: (2021) -
Antiamoebic Properties of Ceftriaxone and Zinc-Oxide–Cyclodextrin-Conjugated Ceftriaxone
por: Makhlouf, Zinb, et al.
Publicado: (2022) -
Molecular Epidemiology of Ceftriaxone-Nonsusceptible Enterobacterales Isolates in an Academic Medical Center in the United States
por: Tamma, Pranita D, et al.
Publicado: (2019)